Lithium Carbonate Pill — Competitive Intelligence Brief

Lithium Carbonate Pill (Lithium Carbonate Pill) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mood stabilizer. Area: Psychiatry.

marketed Mood stabilizer Glycogen synthase kinase-3 (GSK-3), inositol monophosphatase Psychiatry Small molecule

Target snapshot

Lithium Carbonate Pill (Lithium Carbonate Pill) — Shanghai Mental Health Center. Lithium carbonate modulates intracellular signaling pathways, particularly inhibiting inositol monophosphatase and glycogen synthase kinase-3 (GSK-3), which stabilizes mood and reduces manic and depressive episodes.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lithium Carbonate Pill TARGET	Lithium Carbonate Pill	Shanghai Mental Health Center	marketed	Mood stabilizer	Glycogen synthase kinase-3 (GSK-3), inositol monophosphatase
Lithobid	lithium carbonate	Generic (multiple manufacturers)	marketed	Mood stabilizer	Inositol-1(or 4)-monophosphatase 1, Glycogen synthase kinase-3	1970-04-06
Tegretol	carbamazepine	Novartis AG (originally Geigy)	marketed	Mood Stabilizer [EPC]	Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4	1968-03-11
CARBAMAZEPINE	CARBAMAZEPINE		marketed	Mood Stabilizer [EPC]		1968-01-01
Divalproex (DV)	Divalproex (DV)	Weill Medical College of Cornell University	marketed	Histone deacetylase inhibitor; anticonvulsant; mood stabilizer	Histone deacetylase; GABA metabolism; sodium and calcium channels
Lithium / Fluoxetine	Lithium / Fluoxetine	University of Pennsylvania	marketed	SSRI + mood stabilizer combination	Serotonin transporter (SERT); inositol monophosphatase
lamotrigine (generic Teva)	lamotrigine (generic Teva)	University of Maryland, Baltimore	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2028-11-10 — Tegretol · 9770407 · Formulation · US
• 2028-11-10 — Tegretol · 9629797 · Method of Use · US
• 2029-03-13 — Tegretol · 9750822 · Formulation · US
• 2029-03-13 — Tegretol · 7635773 · Formulation · US
• 2029-03-13 — Tegretol · 8410077 · Formulation · US
• 2033-02-27 — Tegretol · 9493582 · Formulation · US
• 2040-01-31 — Tegretol · 11529357 · Formulation · US

Sponsor landscape (Mood stabilizer class)

1. Shanghai Mental Health Center · 2 drugs in this class
2. Generic (multiple manufacturers) · 1 drug in this class
3. National Cheng-Kung University Hospital · 1 drug in this class
4. AstraZeneca · 1 drug in this class
5. University of Aarhus · 1 drug in this class
6. University of Milan · 1 drug in this class
7. Weill Medical College of Cornell University · 1 drug in this class